首頁 > 市場調查報告書 > 製藥

醫藥品原料藥

市場調查報告書

商品編碼

1609657

2025-2033 年日本活性藥物成分市場報告（按藥物類型、製造商類型、合成類型、治療應用和地區）

Japan Active Pharmaceutical Ingredients Market Report by Drug Type, Type of Manufacturer, Type of Synthesis, Therapeutic Application, and Region 2025-2033

出版日期: 2024年12月05日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024 年日本活性藥物成分 (API) 市場IMARC Group達到 279 億美元。對生物相似藥和學名藥的需求不斷增加，加上臨床試驗數量不斷增加，主要推動了市場的成長。

活性藥物成分 (API) 是藥物的重要組成部分，可確保它們達到預期的治療效果。這些生物活性化合物對於治療和控制許多健康問題的症狀至關重要。它們是透過複雜的化學和生物方法製成的，其純度、強度和一致性對其藥效至關重要。 API 可以對多種疾病進行特定治療，使製藥公司能夠針對特定疾病和人群開發適合的藥物。它們被納入各種藥物形式，如丸劑、膠囊、乳膏或注射劑，每種形式都有獨特的製造需求。與此一致，活性藥物成分有助於藥物傳遞技術的進步，增強藥物在人體內的有效和安全的分散。

日本活性藥物成分 (API) 市場趨勢：

日本的活性藥物成分市場正在大幅成長，這主要是由其製藥領域的指數級發展所推動的。隨著日本努力應對各種慢性病日益流行的問題，對 API 的需求不斷增加，這反映了新興趨勢。推動日本這一市場軌蹟的一個顯著因素是其製藥巨頭的深入研究和開發工作。此外，他們尋求推出增強型產品迭代，特別是高效活性藥物成分，為國家原料藥市場描繪了一幅樂觀的圖景。除此之外，日本製藥業在全球健康危機期間取得的前所未有的進展進一步放大了該市場的勢頭。同時，日本作為技術發展的熱點，正在生物技術和生命科學領域取得突破，這些因素正在塑造其 API 格局。研究機構數量的增加和臨床探索的增加預示著成長潛力。再加上城市的快速擴張、日本老年人口的迅速成長以及政府和私人實體為完善醫療基礎設施而進行的大量投資，顯然日本的活性藥物成分市場在可預見的未來將持續成長。

日本活性藥物成分 (API) 市場細分：

藥物類型見解：

創新活性藥物成分（API）
學名藥活性成分 (API)

製造商洞察類型：

專屬製造商
商家 API 製造商
創新商業 API 製造商
通用商家 API 製造商

綜合見解的類型：

合成活性藥物成分 (API)
類型
創新的合成原料藥
通用合成 API
生物技術活性藥物成分 (API)
類型
創新生物技術 API
生物相似藥
產品
單株抗體
疫苗
細胞因子
融合蛋白
治療酵素
血液因素
表達系統
哺乳動物表達系統
微生物表現系統
酵母表現系統
基因改造動物系統
其他

治療應用見解：

腫瘤學
心血管和呼吸系統
糖尿病
中樞神經系統疾病
神經系統疾病
其他

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本活性藥物成分 (API) 市場迄今表現如何，未來幾年又將如何表現？
COVID-19 對日本活性藥物成分 (API) 市場有何影響？
日本活性藥物成分 (API) 市場按藥物類型分類是怎樣的？
日本活性藥物成分 (API) 市場按製造商類型分類是怎樣的？
日本活性藥物成分 (API) 市場以合成類型分類是怎樣的？
日本活性藥物成分 (API) 市場在治療應用方面的詳細情形如何？
日本活性藥物成分（API）市場價值鏈的各個階段是什麼？
日本活性藥物成分（API）的關鍵促進因素和挑戰是什麼？
日本活性藥物成分 (API) 市場的結構如何？
日本原料藥（API）市場的競爭程度如何？

本報告回答的關鍵問題：

日本活性藥物成分 (API) 市場迄今表現如何，未來幾年又將如何表現？
COVID-19 對日本活性藥物成分 (API) 市場有何影響？
日本活性藥物成分 (API) 市場按藥物類型分類是怎樣的？
日本活性藥物成分 (API) 市場按製造商類型分類是怎樣的？
日本活性藥物成分 (API) 市場以合成類型分類是怎樣的？
日本活性藥物成分 (API) 市場在治療應用方面的詳細情形如何？
日本活性藥物成分（API）市場價值鏈的各個階段是什麼？
日本活性藥物成分（API）的關鍵促進因素和挑戰是什麼？
日本活性藥物成分 (API) 市場的結構如何？
日本原料藥（API）市場的競爭程度如何？

合成活性藥物成分 (API)
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場區隔
  - 類型
    - 創新的合成原料藥
    - 通用合成 API
- 市場預測（2025-2033）
生物技術活性藥物成分 (API)
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場區隔
  - 類型
    - 創新生物技術 API
    - 生物相似藥
  - 產品
    - 單株抗體
    - 疫苗
    - 細胞因子
    - 融合蛋白
    - 治療酵素
    - 血液因素
  - 表達系統
    - 哺乳動物表達系統
    - 微生物表現系統
    - 酵母表現系統
    - 基因改造動物系統
    - 其他
- 市場預測（2025-2033）

第 9 章：日本活性藥物成分 (API) 市場 - 細分：按治療應用分類

腫瘤學
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
心血管和呼吸系統
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
糖尿病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
中樞神經系統疾病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
神經系統疾病
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
其他
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）

第 10 章：日本活性藥物成分 (API) 市場 - 競爭格局

概述
市場結構
市場參與者定位
最佳制勝策略
競爭儀表板
公司評估象限

第 11 章：關鍵參與者簡介

Company A

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company B

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company C

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company D

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company E

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

第 12 章：日本活性藥物成分 (API) 市場 - 產業分析

促進因素、限制因素和機會
- 概述
- 促進要素
- 限制
- 機會
波特五力分析
- 概述
- 買家的議價能力
- 供應商的議價能力
- 競爭程度
- 新進入者的威脅
- 替代品的威脅
價值鏈分析

第 13 章：附錄

簡介目錄

Product Code: SR112024A16298

Japan active pharmaceutical ingredients (API) market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 43.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5% during 2025-2033. The increasing need for biosimilars and generic drugs, coupled with the growing number of clinical trials, is primarily driving the market growth.

Active pharmaceutical ingredients (APIs) are essential components of medications, ensuring they deliver the desired healing outcomes. These biologically active compounds are vital in treating and managing symptoms of numerous health issues. They are crafted through intricate chemical and biological methodologies, with their purity, strength, and consistency being critical for their medicinal efficacy. APIs enable specific treatments for a wide range of illnesses, allowing pharmaceutical companies to create drugs tailored to specific diseases and populations. They are incorporated in various drug formats, such as pills, capsules, creams, or injections, each with unique manufacturing needs. In line with this, active pharmaceutical ingredients contribute to the progression of drug delivery techniques, enhancing the efficient and safe dispersion of drugs within the human body.

Japan Active Pharmaceutical Ingredients (API) Market Trends:

The active pharmaceutical ingredients market in Japan is witnessing substantial growth, driven predominantly by the exponential progression in its pharmaceutical domain. As Japan grapples with a rising prevalence of various chronic ailments, there's a heightened demand for APIs, mirroring emerging trends. A notable factor propelling this market trajectory in Japan is the intensive research and development endeavors by its pharmaceutical giants. Additionally, their quest to launch enhanced product iterations, especially high-potency active pharmaceutical ingredients, paints an optimistic picture for the nation's API market. Besides this, the unprecedented strides taken by the Japanese pharmaceutical sector during global health crises further amplify this market's momentum. Concurrently, Japan, being a hotspot of technological evolution, is experiencing breakthroughs in biotechnology and life sciences, factors that are auspiciously shaping its API landscape. An augmented count of research institutions and the uptick in clinical explorations signify the growth potential. Compounded by the rapid urban sprawl, Japan's burgeoning elderly demographic, and substantial investments by both governmental and private entities towards refining the healthcare infrastructure, it's evident that Japan's active pharmaceutical ingredients market is poised for sustained growth in the foreseeable future.

Japan Active Pharmaceutical Ingredients (API) Market Segmentation:

Drug Type Insights:

Innovative Active Pharmaceutical Ingredients (API)
Generic Active Pharmaceutical Ingredients (API)

Type of Manufacturer Insights:

Captive Manufacturers
Merchant API Manufacturers
Innovative Merchant API Manufacturers
Generic Merchant API Manufacturers

Type of Synthesis Insights:

Synthetic Active Pharmaceutical Ingredients (API)
Type
Innovative Synthetic APIs
Generic Synthetic APIs
Biotech Active Pharmaceutical Ingredients (API)
Type
Innovative Biotech APIs
Biosimilars
Product
Monoclonal Antibodies
Vaccines
Cytokines
Fusion Proteins
Therapeutic Enzymes
Blood Factors
Expression System
Mammalian Expression Systems
Microbial Expression Systems
Yeast Expression Systems
Transgenic Animal Systems
Others

Therapeutic Application Insights:

Oncology
Cardiovascular and Respiratory
Diabetes
Central Nervous System Disorders
Neurological Disorders
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan active pharmaceutical ingredients (API) market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan active pharmaceutical ingredients (API) market?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of drug type?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of type of manufacturer?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of type of synthesis?
What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of therapeutic application?
What are the various stages in the value chain of the Japan active pharmaceutical ingredients (API) market?
What are the key driving factors and challenges in the Japan active pharmaceutical ingredients (API)?
What is the structure of the Japan active pharmaceutical ingredients (API) market and who are the key players?
What is the degree of competition in the Japan active pharmaceutical ingredients (API) market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Active Pharmaceutical Ingredients (API) Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Active Pharmaceutical Ingredients (API) Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Drug Type

6.1 Innovative Active Pharmaceutical Ingredients (API)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Generic Active Pharmaceutical Ingredients (API)
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Type of Manufacturer

7.1 Captive Manufacturers
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Merchant API Manufacturers
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Segmentation
  - 7.2.3.1 Innovative Merchant API Manufacturers
  - 7.2.3.2 Generic Merchant API Manufacturers
- 7.2.4 Market Forecast (2025-2033)

8 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Type of Synthesis

8.1 Synthetic Active Pharmaceutical Ingredients (API)
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Segmentation
  - 8.1.3.1 Type
    - 8.1.3.1.1 Innovative Synthetic APIs
    - 8.1.3.1.2 Generic Synthetic APIs
- 8.1.4 Market Forecast (2025-2033)
8.2 Biotech Active Pharmaceutical Ingredients (API)
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Segmentation
  - 8.2.3.1 Type
    - 8.2.3.1.1 Innovative Biotech APIs
    - 8.2.3.1.2 Biosimilars
  - 8.2.3.2 Product
    - 8.2.3.2.1 Monoclonal Antibodies
    - 8.2.3.2.2 Vaccines
    - 8.2.3.2.3 Cytokines
    - 8.2.3.2.4 Fusion Proteins
    - 8.2.3.2.5 Therapeutic Enzymes
    - 8.2.3.2.6 Blood Factors
  - 8.2.3.3 Expression System
    - 8.2.3.3.1 Mammalian Expression Systems
    - 8.2.3.3.2 Microbial Expression Systems
    - 8.2.3.3.3 Yeast Expression Systems
    - 8.2.3.3.4 Transgenic Animal Systems
    - 8.2.3.3.5 Others
- 8.2.4 Market Forecast (2025-2033)

9 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Therapeutic Application

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Cardiovascular and Respiratory
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Diabetes
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Central Nervous System Disorders
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2019-2024)
- 9.4.3 Market Forecast (2025-2033)
9.5 Neurological Disorders
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2019-2024)
- 9.5.3 Market Forecast (2025-2033)
9.6 Others
- 9.6.1 Historical and Current Market Trends (2019-2024)
- 9.6.2 Market Forecast (2025-2033)

10 Japan Active Pharmaceutical Ingredients (API) Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Active Pharmaceutical Ingredients (API) Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis